Dataset Information


Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.

ABSTRACT: TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at a single-institution showed a trend towards better overall survival (OS) for patients who experienced chemotherapy-induced neutropenia at 1-month (CIN-1-month). To explore this finding further, a cohort study was designed based on outcome data from three centers in United States and one from Japan.CIN-1-month after starting TAS-102 was defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 as a neutrophil count decrease of???grade 2 (absolute neutrophil count?


PROVIDER: S-EPMC4944251 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5239803 | BioStudies
2017-01-01 | S-EPMC5635852 | BioStudies
2020-01-01 | S-EPMC7467965 | BioStudies
2017-01-01 | S-EPMC5834058 | BioStudies
2020-01-01 | S-EPMC7514061 | BioStudies
2012-01-01 | S-EPMC3405214 | BioStudies
2020-01-01 | S-EPMC7599669 | BioStudies
2017-01-01 | S-EPMC7497848 | BioStudies
2019-01-01 | S-EPMC6909918 | BioStudies
2020-01-01 | S-EPMC7364795 | BioStudies